LV-SMART™-LVVs Suspension Production Platform

Get in Touch

LV-SMART®-LVVs Suspension Production Platform

In the early stages of viral vector preparation, adherent cells containing bovine serum were most commonly used for production. However, not only were the costs high, but it also proved difficult to scale up and posed great challenges to safety assurance, specifically in the form of exogenous factors. This method also has high requirements for material, production process, and cost control. To address these challenges, the switch to suspension production of viral vectors was an inevitable change. Our senior experts and technical team at Porton Advanced have developed a proprietary suspension serum-free production platform called LV-SMART®, which adheres to relevant regulations and builds off our experience in virology, bioprocessing, and quality control.

Our LV-SMART® platform simplifies the production process for fast project delivery. Porton Advanced’s proprietary HEK293T cell line enables a high virus titer and is easy to scale up without animal-derived components as raw materials. Additionally, we have developed a unique purification technology with high recovery rates, low residues, and a high infectious titer.  With this innovative and well-established platform, it takes us only 7 months to go from microbial banking to the first cell product primary batch delivery. 

Why choose LV-SMART® platform?

Features

  • Proprietary HEK293T
    Clonally screened
    Acclimated suspension
    Clear traceability
  • Serum-free Suspension GMP Manufacturing Process
    Amenable for scale-up
  • Characterized Master Cell Bank and Working Cell Bank
    Ready for lentiviral vector production
    Expedited project execution and delivery
    FDA DMF registered
  • Proprietary Lentiviral Vector Purification Processes
    High viral titer (higher than 5E07 TU/ml)
    Low impurity
  • Applied to extensive CRO & CDMO projects
    250+ CRO projects (CRO feasibility studies before CMC projects)
    14+ IND and clinical-stage CMC projects
  • Proprietary Lentiviral Vector Purification Processes
    High viral titer (higher than 5E07 TU/ml)
    Low impurity

    Experienced in ex-vivo / in vivo CAR-T, TCR-T, Dual targeting CAR-T, and CAR-NK projects
    Experienced in LV pseudotyped with VSV-G, BAEV, and Cocal

Applied to extensive CRO & CDMO projects

Ready-to-use Cell Bank with Registered FDA DMF Files

The HEK293T cell line used in our LV-SMART® platform was developed through clonal screening and suspension adaptation. It has clear traceability and full records of cell line development, cell recovery, and passage. The cell line established two-tiered cell banks (master cell bank and work cell bank), which are both applicable for IND application in the US and China. The master files for MCB and WCB have been received by the Center for Biologics Evaluation and Research (CBER).

Case Study

The LV-SMART® Platform has been used for different Lentiviral vectors' envelopes with different GOIs projects.

The crude titer for lentiviral vectors pseudotyped with VSV-G, BAEV, and Cocal and with different GOIs is over 5E07TU/mL.

Clients & Partners

View More